UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION
                             Washington, D.C. 30549




                                   FORM 10-QSB




(MarkOne)

[X]  QUARTERLY  REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES  EXCHANGE ACT
     OF 1934
                                   For the quarterly period ended March 31, 2002

[  ] TRANSACTION REPORT UNDER SECTION 13 OR 15(d) OF THE EXCHANGE ACT
                        For the transition period from            to
                                                       ----------    -----------

                                                 Commission file number: 0-27489
                                                                         -------

                                 DuraVest, Inc.
        -----------------------------------------------------------------
        (Exact name of small business issuer as specified in its charter)

            Florida                                              59-2624574
-------------------------------                              -------------------
(State or Other Jurisdiction of                              (IRS Employer
Incorporation or Organization)                               Identification No.)

        1543 Bayview Avenue, Suite 409, Toronto, Ontario, Canada M4G3B5
        ---------------------------------------------------------------
                    (Address of principal executive offices)

                                 (416) 271-5285
                           ---------------------------
                           (Issuer's telephone number)


               ---------------------------------------------------
               (Former name, former address and former fiscal year
                         (if changed since last report)




                APPLICABLE ONLY TO ISSUERS INVOLVED IN BANKRUPTCY
                   PROCEEDINGS DURING THE PRECEDING FIVE YEARS

Check whether the  registrant  filed all  documents  and reports  required to be
filed by Section 12, 13 or 15(d) of the Exchange Act after the  distribution  of
securities under a plan confirmed by a Court. Yes [ ] No [ ]




                      APPLICABLE ONLY TO CORPORATE ISSUERS

The  number of shares  outstanding  of each of the  issuer's  classes  of common
equity, as of March 31, 2002 was 3,676,664 shares of common stock.

Transitional Small Business Disclosure Format (Check one):  Yes [X]  No [  ]

<PAGE>

                                      INDEX

                                                                           Page
                                                                          Number
                                                                          ------

Part I.  Financial Information


     Item 1.  Financial Statements

              Condensed Balance Sheets as of March 31, 2002
              and December 31, 2001                                         3

              Condensed Statements of Loss for the Three
              Months Ended March 31, 2002 and March 31, 2001
              and since Inception                                           4

              Condensed Statements of Cash Flows for the Three
              Months Ended March 31, 2002 and March 31, 2001
              and since Inception                                           5

              Notes to Financial Statements                                 6

     Item 2.  Plan of Operation                                            10


Part II. Other Information

     Item 1.  Legal Proceedings                                            13

     Item 2.  Changes in Securities                                        13

     Item 3.  Defaults in Senior Securities                                13

     Item 4.  Submission of Matters to a Vote of Securities Holders        13

     Item 5.  Other Information                                            13

     Item 6.  Exhibits and Reports on Form 8-K                             13



                                       2
<PAGE>

                         PART I - FINANCIAL INFORMATION


Item 1.  Financial Statements
-----------------------------




                                 Duravest, Inc.
                            Condensed Balance Sheets
                             (A Development Company)
                                   (Unaudited)

                                                    03/31/2002       12/31/2001

                                     ASSETS


CURRENT ASSETS
  Cash                                                $ 25,952         $ 40,545
                                                      --------         --------

TOTAL ASSETS                                          $ 25,952         $ 40,545
                                                      ========         ========


                                 LIABILITIES AND
                              STOCKHOLDERS' EQUITY


LIABILITIES:
  Accounts Payable                                    $    800         $  6,766
                                                      --------         --------
      TOTAL LIABILITIES                               $    800         $  6,766


STOCKHOLDERS' EQUITY
  Preferred Stock, $.0001 par
    value; authorized 20,000,000 shares
    no issued and outstanding shares
  Common Stock, $.0001 par value; authorized
    80,000,000 shares, issued and
    outstanding 36,766,640 and 36,766,640
    shares at March 31, 2002 and
    December 31, 2001                                    3,680            3,680
  Additional Paid-in Capital                           448,820          448,820
  Accumulated Deficit                                 (427,348)        (418,721)
                                                      --------         --------
      TOTAL STOCKHOLDERS' EQUITY                        25,152           33,779
                                                      --------         --------

TOTAL LIABILITIES AND
  STOCKHOLDERS' EQUITY                                $ 25,952         $ 40,545
                                                      ========         ========



                                       3
<PAGE>

                                 Duravest, Inc.
                          Condensed Statements of Loss
                          (A Development Stage Company)
                                   (Unaudited)


                                     -------------------------------------------
                                               Three Months           Since
                                          3/31/02        3/31/01      Inception
                                     -------------------------------------------

REVENUES:
    TOTAL REVENUES                     $        0      $       0      $       0


EXPENSES
    DEVELOPMENT STAGE EXPENSES              8,579         17,420        426,640

    REMEASUREMENT LOSS (GAIN)                  48             83            708
                                       ----------      ---------      ---------
      NET LOSS                         $  (20,780)     $ (17,503)     $(427,348)
                                       ==========      =========      =========


Loss per common share
  basic earnings per share             $     (.01)     $    (.01)
                                       ==========      =========

Weighted average shares
  outstanding                          36,766,640      3,676,664
                                       ==========      =========



                                       4
<PAGE>
<TABLE>
<CAPTION>

                                            Duravest, Inc.
                                  Condensed Statements of Cash Flows
                                     (A Development Stage Company)
                                              (Unaudited)

                                                                                    -----------------------------       ------------
                                                                                     For the Three Months Ended             Since
                                                                                              March 31,                   Inception
                                                                                    -----------------------------       ------------
                                                                                      2002                2001
<S>                                                                                 <C>                 <C>               <C>
CASH FLOWS FROM OPERATING ACTIVITIES
  Cash Paid for Operating Expenditures                                              $(14,593)           $(17,503)         $(426,548)
NET CASH UTILIZED BY                                                                --------            --------          ---------
  OPERATING ACTIVITIES:                                                              (14,593)            (17,503)          (426,548)


CASH FLOWS FROM FINANCING ACTIVITIES
  Proceeds from issuance of common stock                                                   -                   -            452,500
NET CASH PROVIDED BY                                                                --------            --------          ---------
  FINANCING ACTIVITIES:                                                                    -                   -            452,500

NET INCREASE (DECREASE) IN CASH                                                      (14,593)            (17,503)            25,952
CASH & EQUIVALENTS AT JANUARY 1,                                                      40,545              98,571                  -
                                                                                    --------            --------           --------
CASH & EQUIVALENTS AT MARCH 31,                                                     $ 25,952            $ 81,068           $ 25,952
                                                                                    ========            ========           ========

Reconciliation of excess revenues over expenses
  to net cash provided (used) by operating activities:

Excess of revenues over expenses                                                      (8,627)            (17,503)          (427,348)

Adjustments to reconcile excess revenues
  over expenses to net cash provided (used)
  by operating activities:
Accounts Payable                                                                      (5,966)                                   800
                                                                                    --------            --------          ---------
Net Cash Provided (Utilized) by
Operating Activities                                                                $(14,593)           $(17,503)         $(426,548)
                                                                                    ========            ========          =========



                                                          5
</TABLE>



<PAGE>

Duravest, Inc.
(A Development Stage Company)
Notes to the Condensed Financial Statements

NOTE 1 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Basis of Presentation
---------------------

The accompanying  unaudited condensed financial statements have been Prepared in
accordance with generally accepted  accounting  principles for interim financial
information  and with Article 10 of  Regulation  S-X.  Accordingly,  they do not
include all of the  information  and  footnotes  required by generally  accepted
accounting principles for complete financial statements.  All adjustments which,
in the opinion of management,  are considered  necessary for a fair presentation
of the results of  operations  for the periods  shown are of a normal  recurring
nature and have been reflected in the unaudited condensed financial  statements.
The  results  of  operations  for the  periods  presented  are  not  necessarily
indicative  of the results  expected  for the full fiscal year or for any future
period.  The  information   included  in  these  unaudited  condensed  financial
statements  should be read in conjunction  with Plan of Operation and Results of
Operations   contained  in  this  report  and  the  financial   statements   and
accompanying notes included in the Great Wall Food and Beverage Corporation (the
"Company")  Annual  Report on Form 10-K for the fiscal year ended  December  31,
2001.

Business and Organization
-------------------------

Great Wall Food and Beverage  Corporation (the "Company"),  a development  stage
company,  was  incorporated  in the State of Florida on August 1, 1980 as Ronnie
Interior Designs,  Inc. for the purpose of acquiring or merging with an existing
operating company.

On October 14, 1997,  Ronnie Interior  Designs,  Inc. changed its name to Ronnie
Systems, Inc.

On  March  13,  1998,   the  Company   amended  and  restated  its  articles  of
incorporation and changed its name to Great Wall Food and Beverage Corporation.

On  November  9,  2001,  the  Company  amended  and  restated  its  articles  of
incorporation and changed its name to Duravest, Inc.

Development Stage
-----------------

The Company has operated as a development  stage  enterprise since its inception
by devoting  substantially  all its efforts to the  ongoing  development  of the
Company.

Accounting Method
-----------------

The Company's  financial  statements  are prepared  using the accrual  method of
accounting. The Company has elected a calendar year end of December 31.


                                       6
<PAGE>


Loss per Share
--------------

The  computation  of loss per share of common  stock is based upon the  weighted
average common shares outstanding during each period.

Development Stage
-----------------

The Company has operated as a development  stage  enterprise since its inception
by devoting  substantially all of its efforts to the ongoing  development of the
Company.

Foreign Currency Translation
----------------------------

During 1999 the Company opened a bank account  denominated in a foreign currency
which  is used  to pay for  some  operational  expenses.  The  bank  account  is
translated  using rates of exchange  at March 31,  2002 and 2001;  expenses  are
translated at weighted  average  exchange  rates in effect during the year.  The
cumulative  effect  resulting from such translation is recorded as remeasurement
gain or loss in the financial statements.

Cash and Cash Equivalents
-------------------------

The Company considers cash and all highly liquid  investments  purchased with an
original  maturity of less than three  months at the date of purchase to be cash
equivalents.

Fair Value of Financial Instruments
-----------------------------------

Carrying  amounts of certain of the Company's  financial  instruments  including
cash and cash equivalents,  accounts receivable,  notes receivable,  and accrued
liabilities approximate fair value because of their short maturities.

Use of Estimates
----------------

The preparation of financial  statements in conformity  with generally  accepted
accounting principles requires management to make estimates and assumptions that
affect the reported  amounts of assets and  liabilities  and the  disclosure  of
contingent  assets and  liabilities at the date of the financial  statements and
the reported  amounts of expenses  during the reporting  period.  Actual results
could differ from these estimates.

Income Taxes
------------

The Company  accounts for income taxes using the asset and  liability  method as
required by Statement of Financial Accounting Standards No. 109. Deferred income
taxes are provided on temporary differences between book and tax income, arising
primarily from the use of differing methods of recognition of start-up costs. An
allowance  is provided  if it is more likely than not that the Company  will not
realize the benefits of a deferred tax asset.


                                       7
<PAGE>


NOTE 2 - STOCKHOLDER'S EQUITY

The Company had the following classes of capital stock:

Series A Preferred  Stock,  $0.0001  par value;  authorized  20,000,000  shares;
issued and outstanding -0- shares.

Common stock, $0.0001 par value, 80,000,000 shares authorized, 36,766,640 shares
issued and outstanding at March 31, 2002 and December 31, 2001 respectively.

NOTE 3 - GOING CONCERN

The Company's  financial  statements are prepared  using the generally  accepted
accounting  principles  applicable to a going concern,  which  contemplates  the
realization  of assets and  liquidation  of  liabilities in the normal course of
business.  However,  the  Company  has no  current  source of  revenue.  Without
realization  of  additional  capital,  it would be  unlikely  for the Company to
continue as a going concern.  It is  management's  intention to seek  additional
capital through a merger with an existing operating company and raising capital.

NOTE 4 - INCOME TAXES

For  financial  reporting  purposes,  a valuation  allowance of $79,081 has been
recognized to offset the net deferred tax assets related to these  carryforwards
and other deferred tax assets since  realization of any portion of the Company's
deferred tax asset is not  considered  to be more likely than not. The change in
the  valuation  allowance  for the years  ended  December  31, 2001 and 2000 was
$22,171 and $12,210 respectively.

Deferred income taxes reflect the net effects of temporary  differences  between
the carrying amounts of assets and liabilities for financial  reporting purposes
and the amounts  used for income tax  purposes.  Significant  components  of the
Company's deferred tax liabilities and assets are as follows:

                                            2001         2000
     Deferred tax assets:
     Net operating loss carryforwards    $ 79,081      $56,910
                                         --------      -------
     Total deferred tax assets             79,081       56,910
     Valuation allowance for
       deferred tax assets                (79,081)     $56,910)
                                         --------      -------
                                                0            0
                                         ========      =======

The Company has incurred net operating losses since  inception.  At December 31,
2001 and 2000 the Company had  approximately  $395,407 and $284,549 in operating
loss carryforwards that expire in various amounts from 2015 through 2021.



                                       8
<PAGE>


NOTE 5 - RELATED PARTY TRANSACTIONS

The Company neither owns or leases any real property.  Fees totaling $0 and $500
were paid to companies owned by shareholders  during the periods ended March 31,
2002 and 2001 for administrative  and consulting  services rendered on behalf of
the Company.  The  officers  and  directors of the Company are involved in other
business  activities and may, in the future,  become  involved in other business
opportunities.

NOTE 6 - SUBSEQUENT EVENTS

On April 4, 2002 the Company entered into a conditional stock exchange agreement
with Cardio Management Systems,  Inc.("Cardio"),  a corporation  organized under
the  Canadian  Business  Corporation  Act.  Under  the  agreement,   if  certain
conditions are met, the Company will issue 5,000,000  shares of its common stock
in exchange for  1,000,000  shares of Cardio  stock and as a result  Cardio will
become a wholly owned  subsidiary.  The principal assets of Cardio are shares of
common stock of Estracure, Inc. ("Estracure"), a corporation organized under the
Canadian  Business  Corporation Act and an optional right to acquire  additional
shares  of  Estracure  common  stock,  at no time to  exceed  50%  ownership  of
Estracure outstanding common stock. If the stock exchange is completed the stock
of Estracure  owned by Cardio could be considered to be "investment  securities"
as such are  defined  by the  Investment  Company  Act of 1940 ("40  Act").  The
condition precedent to the completion of the stock exchange shall be the receipt
by  Duravest,  Inc.  of either (1) a  "no-action"  letter  from the SEC that the
completion of the stock exchange with the resultant ownership by Duravest,  Inc.
of Cardio with its investment in Estracure (with Estracure not being a "majority
owned  subsidiary" of Cardio under the 40 Act) will not cause a violation of the
40 Act; or (2) an opinion of counsel that the  completion of the stock  exchange
with the resultant ownership by Duravest,  inc. of Cardio with its investment in
Estracure  (with  Estracure not being a "majority  owned  subsidiary"  of Cardio
under the 40 Act)  will not  cause a  violation  of the 40 Act.  Duravest,  Inc.
intends to pursue the  satisfaction  of either or both of these two  conditions.
However, there is no assurance that it will be able to satisfy either of them.




                                       9
<PAGE>


Item 2.  Plan of Operation
-------  -----------------

     DuraVest,  Inc. (the "Issuer" or  "DuraVest")  is continuing its efforts to
find a new business opportunity.  The Issuer will seek and attempt to enter into
a business  combination of acquisition or assets by which it will become engaged
in an active business venture. It is likely that, if such a transaction is made,
it will involve  control of the Issuer being  acquired by the other party to the
transaction.

     On April 4, 2002 the  Issuer  entered  into a  Conditional  Stock  Exchange
Agreement  ("Exchange  Agreement")  with  Cardio  Management  Systems,  Inc.,  a
corporation organized under the Canada Business Corporation Act ("Cardio"),  and
Ms. Patti Cooke,  the sole record  stockholder  of Cardio.  (Ms. Cooke holds the
Cardio shares as a nominee for undisclosed principals. She is also the President
and a director  of the  Issuer.)  Under the  Exchange  Agreement,  if  specified
conditions  are met,  the Issuer will  acquire all of the  outstanding  stock of
Cardio in exchange  for  5,000,000  shares of the  Issuer's  common  stock.  The
Issuer's stock would be issued as  "restricted  securities " as such are defined
under the  Securities  Act of 1933.  They would be issued in  reliance  upon the
exemption from registration under Section 5 of that Act provided in Section 4(2)
thereof or Regulation D adopted thereunder.

     Cardio was recently formed to provide funds to and acquire an investment in
Estracure, Inc., a Canadian corporation (Estracure").  Cardio has acquired 26 of
the 100 shares of Estracure  presently  outstanding for which it paid $2,500,000
(Canadian - which  equated to $1,590,000  U.S. as of May 8, 2002).  Estracure is
involved  in the  research,  development  and  commercialization  of the  use of
"Estradiol" to reduce restenosis after  angioplasty (see additional  description
following).  If the  undergoing  human  clinical  trails of Estradiol are deemed
successful,  Cardio has the option to acquire  sufficient  additional  shares of
Estracure  to bring  its  ownership  interest  therein  to 50% in  exchange  for
$7,500,000 Canadian ($4,750,000 U.S. as of May 8, 2002).

     The  contractual  arrangements  between  Cardio and Estracure  provide that
Cardio may not, at any time,  acquire  more than 50% of the  outstanding  common
stock of  Estracure  (which  prohibition  is  designed to protect  valuable  and
favorable  Canadian  Tax  treatment  for  Estracure  and its  shareholders).  If
DuraVest  acquires the stock of Cardio it could be considered to be  "investment
securities"  as such are defined under the  Investment  Company Act of 1940 ("40
Act") and their  ownership  by Cardio as a wholly owned  subsidiary  of DuraVest
could cause DuraVest to become an unregistered  inadvertent  investment  company
under the 40 Act. The parties to the Exchange  Agreement  have been advised that
the circumstances of the Cardio investment in Estracure are such that there is a
reasonable  possibility  that:  (i)  DuraVest  could  apply  for  and  obtain  a
"no-action"  letter from the United States  Securities  and Exchange  Commission
("SEC") under which the Cardio  acquisition could be completed without causing a
violation  of  the 40 Act  by  DuraVest;  or  (ii)  if  DuraVest  would  acquire
sufficient additional assets so that the Estracure investment would be less than
40% of its total  assets less cash items,  DuraVest  could  obtain an opinion of
counsel  that  the  completion  of the  Cardio  acquisition  would  not  cause a
violation of the 40 Act by DuraVest.

     Accordingly,  the  completion of the  acquisition  of Cardio by DuraVest is
conditioned upon the receipt of DuraVest of either:

     (i)  A  "no-action"  letter from the SEC that the  completion of the Cardio
          acquisition  with the  resultant  ownership by DuraVest of Cardio with
          its  investment  in Estracure  (with  Estracure  now being a "majority
          owned  subsidiary"  of  Cardio  under  the 40 Act)  will  not  cause a
          violation of the 40 Act; or

     (ii) an opinion of counsel that the  completion  of the Cardio  acquisition
          with the resultant ownership by DuraVest of Cardio with its investment
          in Estracure (with  Estracure not being a "majority owned  subsidiary"
          of Cardio under the 40 Act) will not cause a violation of the 40 Act.

DuraVest  intends  to  pursue  the  satisfaction  of either or both of these two
conditions. However, there is no assurance, it will be able to satisfy either of
them.


                                       10
<PAGE>


     The only material  assets of Cardio are its investment in Estracure and its
option to acquire  additional  stock in  Estracure.  Neither  Cardio or DuraVest
presently have the funds to finance the exercise of Cardio's  options to acquire
additional Estracure stock.  Accordingly,  their ability to exercise this option
will be dependent upon their ability to raise  additional  capital.  There is no
assurance  that:  (I)  Estracure's   human  clinical  trials  of  the  Estradiol
treatments  will be  successful;  (ii) Cardio or DuraVest  will be able to raise
sufficient  capital to exercise the option to acquire the  additional  Estracure
stock; or (iii) Estracure will be able to successfully  develop and commercially
market Estradiol.

     The  shareholders  of  Estracure,  including  Cardio,  have  entered into a
"Shareholders Agreement", the principal provisions of which are as follows:

     (i)  Cardio is entitled to nominate two of the five members of the Board of
          Directors;

     (ii)Subject to the option of Cardio to  subscribe to  additional  shares in
          consideration of the sum of C$7,500,000, the shareholders of Estracure
          benefit from a preemptive right to subscribe,  on a pro rata basis, to
          any additional shares issued to Estracure;

     (iii)a Shareholder  of Estracure may only assign its shares  therein in the
          following circumstances:

          -    The  assignment is made to an affiliate,  subsidiary,  or holding
               company of said shareholder,  provided,  where such a shareholder
               is Cardio and the assignee is DuraVest,  that as a result of such
               assignment,  DuraVest  must not be  considered to have control of
               Estracure  nor,  in  the  opinion  of  Estracure,  may  it  be in
               violation of the Investment Company Act of 1940 (US); or

          -    such  a   shareholder   has  offered  his  shares  to  the  other
               shareholders  who are  entitled  to  acquire  same on a pro  rata
               basis.

     (iv) In the event that one or more shareholders holding,  in the aggregate,
          more than 50% of the issued and outstanding  shares of Estracure which
          to assign their shares to a third party,  the  remaining  shareholders
          may  require  that  their  shares be  purchased  on the same terms and
          conditions.  Inversely, under the same circumstances, the shareholders
          controlling  more than 50% of the  issued  and  outstanding  shares of
          Estracure  may compel  the  remaining  shareholders  to sell to such a
          third party.

     (v)  A  Shareholder  shall be deemed to sell all of its shares in Estracure
          upon the  occurrence  of certain  events,  the  following of which are
          applicable to Cardio:

          -    change  of  control  of  Cardio  except  for its  Acquisition  by
               DuraVest without the unanimous consent of the other  shareholders
               of Estracure;

          -    the  seizure  of a  shareholder's  shares in  Estracure  and such
               seizure is not or contested within 30 days thereof;

          -    the bankruptcy of a shareholder;

          -    fraud by a shareholder;

          -    criminal Act by a shareholder;

          -    the  default  of  a  shareholder  in  respecting  anyone  of  its
               obligation  under the  terms of  Shareholders  Agreement  in such
               default has not been remedied within a reasonable time; and

     (vi) Decisions  in respect of a number of matters have been made subject to
          the  consent  of the  shareholders,  either  by a 75%  majority  or by
          unanimous approval.


                                       11
<PAGE>


     Estracure's  Estradiol  project  has been  developed  by a team of Canadian
medical  researchers  working under the auspices of the Montrea Heart Institute.
They began their  research in 1997 to determine why  arteriosclerosis  and other
diseases  creating  induration of the arteries  occurred more  frequently in men
than women.  They  focused  their  efforts on the  potential  role of  naturally
occurring hormones unique to women in blocking the onset of  arteriosclerosis or
other induration of the arteries.  After  preliminary  trials they focused their
efforts on a form of Estradiol (17-beta Estradiol),  a female sex hormone of the
estrogen family. At this point their goal was to develop a product and treatment
which  would  reduce  the  recurrence  of  blockage   following  an  angioplasty
procedure, a non-surgical  interventional procedure using a tiny balloon to open
blocked  arterial  passages and the use of intravascular  stents.  The Estracure
treatment  involves  the  application  or  injection  of  Estradiol  during  the
angioplasty procedure to impede the re-blocking of the arterial passage.

     The  results  of the  research  to date have been  promising.  The  initial
theoretical  studies have been  followed by work in a more  clinically  relevant
model,  the stent  porcine  coronary  artery  model,  where  there was a renewed
confirmation of restenosis as well as a lower inflammatory score.

     Estracure is now proceeding to set up human  clinical  trials of Estradiol.
If the results of these trials are  satisfactory,  Estracure  intends to proceed
with the research and development of Estradiol and take the necessary actions to
make  it,  including  obtaining  the  necessary  regulatory  approvals.   Before
Estracure can proceed beyond the human clinical trials,  it will have to acquire
additional  funding.  If Cardio is not able to provide capital by exercising its
option, Estracure will have to pursue other sources not now known to it.

     Except for the arrangements with Cardio,  there are no present arrangements
for, or ongoing  negotiations with respect to, all business combination with the
Issuer.  The Issuer has no present knowledge of any other specific candidate for
a business  combination.  The  management  of DuraVest  believes it will have to
acquire  additional  capital to continue its operations over the next 12 months.
If it acquires  Cardio during that period and desires for Cardio to exercise its
option to purchase additional Estracure stock,  DuraVest will have to obtain the
C$7,500,000   necessary  for  the  option  and  additional  capital  to  finance
DuraVest's operations.  There are no present arrangements for the acquisition of
any additional capital or any assurance that such will be available.

     The Issuer has entered into a written  agreement  under which the equipment
manufacturer with whom the Issuer had made a $100,000 advance deposit has agreed
to return the deposit in five monthly  installments  of $20,000 of the first day
of each month  commencing  May 1, 2000.  The Issuer  received  two  payments  of
$20,000 each under the settlement  agreement.  The manufacturer has indicated it
is unable or unwilling to complete the payments. The Issuer is in the process of
beginning collection proceedings against the other party.

                                       12
<PAGE>

                           PART II - OTHER INFORMATION

Item 1.   Legal Proceedings

          Not Applicable


Item 2.   Changes in Securities

          Not Applicable


Item 3.   Defaults in Senior Securities

          Not Applicable


Item 4.   Submission of Matters to a Vote of Securities Holders

          Not Applicable

Item 5.   Other Information

          Not Applicable

Item 6.  Exhibit and Reports on Form 8-K

         (a)      Exhibits:

                  12(d) - Conditional Stock Exchange Agreement with Cardio
                          Management Systems, Inc.

         (b)      Form 8-Ks

                  No  Reports  of Form 8-K were  filed  during  the  three-month
period ended March 31, 2002.


                                   SIGNATURES
                                   ----------

In  accordance  with the Exchange Act, the  registrant  caused this report to be
signed on its behalf by the undersigned, thereunto duly authorized.

                                  DURAVEST, INC.

Dated:  May 14, 2002              By: /s/ Patti Cooke
                                      -----------------------------------------
                                      Patti Cooke, President and Principal
                                      Executive, Accounting Officer and Director

Dated:  May 14, 2002              By: /s/ Bradley R. Wilson
                                      -----------------------------------------
                                      Bradley R. Wilson, Vice President and
                                      Principal Executive Financial Officer and
                                      Director





                                       13